Given the complexities surrounding c-RET and its potential as a therapeutic target for PD30,44, we investigated the therapeutic impact of optoRET21 in our aSyn PD mouse model, aiming to determine whether selective and temporally controlled modulation of c-RET signalling could present a viable alternative to conventional GDNF therapies. The gene discussed is GDNF; the disease is Parkinson disease.